Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis
- PMID: 32238649
- DOI: 10.1248/cpb.c19-00854
Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis
Abstract
Discriminatory drug delivery into target cells is essential to effectively elicit the drug activity and to avoid off-target side effects; however, transporting drugs across the cell membrane is difficult due to factors such as molecular size, hydrophilicity, intercellular adhesiveness, and efflux transporters, particularly, in the brain capillary endothelial cells. Drug delivery into the brain is blocked by the blood-brain barrier (BBB). Thus, developing drugs for the central nervous system (CNS) diseases remains a challenge. The approach based on receptor-mediated transcytosis (RMT) can overcome this impassable problem at the BBB. Well-designed molecules for RMT form conjugates with the ligand and drugs via linkers or nanoparticles. Cell penetrating peptides (CPPs), receptor-targeting peptides, and monoclonal antibodies (mAbs) are often used as ligands. The binding of ligand to the receptor on the endothelial cell surface induces endocytosis. Existing exosomes comprising the conjugates move in the cytoplasm and fuse with the opposite plasma membrane to release them. Subsequently, the transcytosed conjugate-loaded drugs or released drugs from the conjugates elicit activity in the brain. As receptors, transferrin receptor (TfR), low-density lipoprotein receptor (LDLR), and insulin receptor (InsR) have been used to intendedly induce transcytosis. Presently, several clinical trials on CNS drugs for Alzheimer's and Parkinson disease are hindered due to poor drug distribution into the brain. Therefore, this strategy based on RMT is a promising method for CNS drugs to be transported into the brain. In this review, I introduce the practicality and possibility of drug delivery into brain across the BBB using RMT.
Keywords: blood–brain barrier; drug delivery system; ligand–drug conjugate; membrane permeation; nanoparticle; receptor-mediated transcytosis.
Similar articles
-
Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human.Fluids Barriers CNS. 2020 Jul 22;17(1):47. doi: 10.1186/s12987-020-00209-0. Fluids Barriers CNS. 2020. PMID: 32698806 Free PMC article.
-
Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates.Biomedicines. 2022 Jul 5;10(7):1597. doi: 10.3390/biomedicines10071597. Biomedicines. 2022. PMID: 35884906 Free PMC article. Review.
-
Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.BioDrugs. 2018 Dec;32(6):547-559. doi: 10.1007/s40259-018-0309-y. BioDrugs. 2018. PMID: 30306341 Free PMC article.
-
Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery.Expert Opin Drug Deliv. 2023 Jul-Dec;20(12):1789-1800. doi: 10.1080/17425247.2023.2286371. Epub 2023 Dec 29. Expert Opin Drug Deliv. 2023. PMID: 38007619 Free PMC article. Review.
-
Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges.Pharmaceutics. 2022 Mar 18;14(3):672. doi: 10.3390/pharmaceutics14030672. Pharmaceutics. 2022. PMID: 35336049 Free PMC article. Review.
Cited by
-
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.Pharmacol Ther. 2022 May;233:108022. doi: 10.1016/j.pharmthera.2021.108022. Epub 2021 Oct 20. Pharmacol Ther. 2022. PMID: 34687769 Free PMC article. Review.
-
Transferrin-Enabled Blood-Brain Barrier Crossing Manganese-Based Nanozyme for Rebalancing the Reactive Oxygen Species Level in Ischemic Stroke.Pharmaceutics. 2022 May 25;14(6):1122. doi: 10.3390/pharmaceutics14061122. Pharmaceutics. 2022. PMID: 35745695 Free PMC article.
-
Transferrin-Functionalized Liposomes for the Delivery of Gallic Acid: A Therapeutic Approach for Alzheimer's Disease.Pharmaceutics. 2022 Oct 11;14(10):2163. doi: 10.3390/pharmaceutics14102163. Pharmaceutics. 2022. PMID: 36297599 Free PMC article.
-
Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1.PLoS One. 2024 Jun 7;19(6):e0304149. doi: 10.1371/journal.pone.0304149. eCollection 2024. PLoS One. 2024. PMID: 38848430 Free PMC article.
-
Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective.J Nanobiotechnology. 2023 Dec 13;21(1):477. doi: 10.1186/s12951-023-02250-1. J Nanobiotechnology. 2023. PMID: 38087359 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous